Background and aims Millions of people world-wide use websites to help them quit smoking, but effectiveness trials
INTRODUCTION
World-wide, tobacco smoking is the second leading cause of early death and disability [1] , attributable to more than one in 10 deaths [2] . Barriers to accessing smoking cessation treatments include low reimbursement for providers and low consumer demand for traditional treatments [3] . Fortunately, website-delivered interventions provide cessation assistance with high population-level reach [4] . Seventy-nine per cent of US smokers use the internet [5] . Eleven million US smokers each year, and many millions more world-wide, use websites to help them to quit smoking [5] . Compared to telephone quitline interventions, website interventions have: (1) at least 21 times higher overall national reach (11 million for web versus 500 000 for quitlines [5, 6] and (2) lower cost-per-quit (e.g. $291 for web versus $1850 for quitlines [7] ).
Web-delivered cessation interventions have existed for more than 25 years [8] . However, few randomized trials have tested these websites with long-term follow-up, which is critical because of the high level of relapse that occurs by 12 months [8, 9] . These trials have weighted average 12-month follow-up data retention rates of 34% (range = 11-72%). Follow-up rates below 80% can seriously threaten validity [10] .
The weighted average 12-month 30-day point prevalence cessation rate for previous web-delivered intervention trials was 9% (range = 7-17% [8, 9] ). While 9% is higher than the 4% success rate from quitting on one's own, it is much lower than the 14% weighted average success rate of telephone quitlines [11] . Thus, web-delivered interventions have great room for improvement [4, 9] . Overall, there is a need for rigorous randomized trials of web-based cessation interventions with long-term followup, with potential for high population-level impact.
To address these needs, we compared two conceptually distinct websites for smoking cessation. The first was an Acceptance and Commitment Therapy [12] (ACT) website called 'WebQuit'. ACT is a new approach that teaches skills for allowing urges to smoke to pass without smoking, which is conceptually distinct from US Clinical Practice Guidelines (USCPG)-based standard of care approaches that teach avoidance of urges. WebQuit motivates smokers to quit by appealing to their values, whereas the USCPGbased standard approaches motivate using reason and logic. The ACT approach has demonstrated initial feasibility and usefulness for smoking cessation throughout a variety of delivery modalities [13, 14] .
The second website, Smokefree.gov ('Smokefree'), provides the nation's current standard of care for webdelivered smoking cessation in that: (a) its content follows USCPG [15] , (b) it is the most accessed cessation website in the world [3.6 million visits in 2016 (Erik Augustson, 21 April 2017, personal communication)] and (c) it has the highest user satisfaction rates of all non-profit websites for smoking cessation [16, 17] . In a pilot randomized trial, both websites showed promising 3-month follow-up quit rates [14] , and Smokefree has since shown promising 7-month quit rates [17] .
This paper presents the outcomes of a full-scale randomized trial comparing WebQuit with Smokefree on:
• 30-day point prevalence abstinence (PPA) at 12-month follow-up (hypothesis: WebQuit will have higher abstinence rates than Smokefree); • acceptance of cravings and whether changes in acceptance of cravings prospectively predicted abstinence; and • participant engagement and satisfaction.
METHODS

Design
The study was a two-arm randomized controlled trial comparing WebQuit with Smokefree. Participants were recruited on-line, stratified randomized (to avoid chance bias) and surveyed at 12 months, with interim surveys at 3 and 6 months. The 12-month primary end-point accounted for the high levels of relapse rates that occur by 12 months [18, 19] and is directly comparable to the most rigorous trials of web-delivered smoking cessation [8, 9] . Based on the 3-month quit rates observed in our previous pilot trial [14] and relapse rates occurring between 3 and 12 months after randomization [18, 19] , the study was 80% powered for a two-tailed significant difference between a 14.8% WebQuit quit rate and a 10.3% Smokefree quit rate.
Procedures
Participants and enrollment
Adult smokers (n = 2637) were recruited from March 2014 to August 2015. The study participant flow diagram is shown in Fig. 1 . Smokers were recruited nationally via targeted Facebook advertisements, an on-line survey panel, search engine results, friends/family referral, Google advertisements and earned media. The eligibility criteria were: aged 18 years or older; smoked five or more than five cigarettes a day for the last year; ready to quit in the next 30 days; lived in the United States; could read English; access to internet and e-mail; never used Smokefree.gov and were not currently using other cessation treatment; never participated in our prior studies; no household members already enrolled; and willing to be randomized to treatment, to complete three surveys and to provide contact information for themselves and two relatives. Some advertisements were targeted to minorities and enrollment was limited to no more than 75% Caucasian participants, to ensure minority representation.
Participants completed a web-based screening survey and were notified of their eligibility via e-mail. Participants who clicked on their e-mailed link were returned to the study website where they provided consent, completed a baseline survey, completed a contact form and activated the automated randomization algorithm. At each enrollment step, the study was presented as a comparison of 'two web-delivered smoking cessation programs'.
As enrollment occurred on-line, additional actions were taken to ensure that enrollees were actually eligible. These included CAPTCHA (Completely Automated Public Turing test to tell Computers and Humans Apart) authentication, review of internet protocol (IP) addresses for duplicates or non-US origin and review of survey logs for suspicious response times (< 90 seconds to complete screening or < 10 minutes to complete baseline survey). Suspicious cases were contacted by staff. If their information could not be confirmed (n = 80), they were not enrolled.
All study activities were reviewed and approved by the participating sites' Institutional Review Boards.
Randomization
Participants were randomized (1 : 1) to either the experimental intervention (WebQuit.org, n = 1319) or the control intervention (Smokefree.gov, n = 1318). Using randomly permuted block randomization, stratified by daily smoking frequency (≤ 20 versus ≥ 21), education (≤ high school versus ≥ some college) and gender (male versus female). Random assignments were concealed from participants until after study eligibility, consent and baseline data were obtained. Neither research staff nor study participants had access to upcoming randomized study arm assignments.
Blinding and contamination
To ensure participants were blinded to their assigned intervention, each website was branded as "WebQuit" and neither mentioned ACT or Smokefree.gov. Contamination between sites was avoided with a unique user name and password provided only to the individual user and by having an eligibility criterion of not having family, friends or other household members participating.
Follow-up assessment
Participants completed follow-up surveys at 3, 6 and 12 months post-randomization. Participants received $25 for completing each survey and an additional $10 bonus if the on-line survey was completed within 24 hours of initial e-mail invitation to take the survey. People who did not complete the survey on-line were sequentially offered opportunities to do so by phone, mailed survey and then, for main outcomes only, by postcard.
Interventions
WebQuit
WebQuit covered the six core processes in ACT-'values', 'committed action', 'willingness', 'being present', 'cognitive defusion' and 'self-as-context'. The program had four parts.
Step 1, 'make a plan', allowed users to develop a personalized quit plan, identify smoking triggers, learn about Food and Drug Administration (FDA)-approved cessation medications and upload a photograph of their inspiration to quit (ACT processes: 'values and committed action').
Step 2, 'be aware', contained three exercises to illustrate the problems with trying to control thoughts, feelings and physical sensations rather than allowing them to come and go (ACT process: 'creative hopelessness').
Step 3, 'be willing', contained eight exercises to help users practice allowing thoughts, feelings and physical sensations that trigger smoking (ACT processes: 'willingness', 'being present' and 'cognitive defusion').
Step 4, 'be inspired', contained 15 exercises to help participants identify deeply held values inspiring them to quit smoking and to exercise selfcompassion in response to smoking lapses (ACT processes: 'values' and 'self-as-context'). The program also prompted users to track smoking, cessation medications and practice of ACT skills. Tracking results were displayed graphically along with the user's inspiration for quitting and badges earned for program use. The website contained a forum for asking questions about quitting and anytime tips (e.g. a list of tips for dealing with other smokers).
Smokefree
We hosted a secured private version of the Smokefree site. Users were able to navigate through all pages of the website at any time and there were no restrictions on the order in which the content could be viewed. Smokefree had three main sections: 'quit today', 'preparing to quit' and 'smoking issues'. The 'quit today' section had seven pages of content that provide tips for the quit day, staying smoke-free and dealing with cravings. The section also provided information on withdrawal, benefits of quitting and FDA-approved cessation medications. The 'prepare to quit' section had seven content pages providing information on various reasons to quit, what makes quitting difficult, how to make a quit plan and using social support during a quit attempt. The 'smoking issues' section provided five pages on health effects of smoking and quitting, depression, stress, second-hand smoke and coping with the challenges of quitting smoking for the lesbian, gay, bisexual and transgender community. The section also contained five quizzes that provided feedback about level of depression, stress, nicotine dependence, nicotine withdrawal and second-hand smoke, as well as tips for coping with them.
Both interventions were available for login at any time for 12 months after randomization. Neither was modified during the course of the study. For 28 days after randomization, participants in both arms were sent, via text or e-mail (their choice), up to four daily messages (≤ 160 characters) designed to encourage logging in, unless they opted out.
Measures
Baseline measures
At baseline, participants reported on demographics, mental health measures, alcohol use and smoking in their social environment, such as whether they currently lived with a partner who smokes and the number of close friends who smoke regularly. Mental health measures included depression (Center for Epidemiologic Studies Depression Scale: CES-D [20] ), generalized anxiety disorder: GAD-7 [21] , panic disorder (Autonomic Nervous System Questionnaire: ANSQ [22] ), post-traumatic stress disorder (PTSD Checklist: PCL-6 [23] ) and social anxiety (mini-Social Phobia Inventory: SPIN [24] .
Nicotine dependence
Nicotine dependence was measured with the six-item Fagerström Test for Nicotine Dependence (FTND [25] at baseline and 12-month follow-up.
ACT theory-based acceptance process
At baseline and 3-month follow-up, willingness to experience and not act on cravings to smoke (i.e. acceptance) was measured using a nine-item physical sensations subscale of the Avoidance and Inflexibility Scale (adapted from [26, 27] ]). Response choices for each item ranged from 'not at all' (1) to 'very willing' (5). Scores were derived by averaging the items.
Main outcome
For direct comparability with the most rigorous internetbased randomized trials to date [8] , the primary outcome of the study was complete case 30-day point prevalence abstinence (PPA; i.e. no smoking at all in the past 30 days) at 12-month follow-up. Due to low demand characteristics for false reporting, the SRNT Subcommittee on Biochemical Verification recommended that biochemical confirmation is unnecessary in population-based studies with no face-to-face contact and studies where data are collected optimally through the web, telephone or mail [28] . Selfreported smoking is a standard method for assessing the efficacy of web-delivered interventions [8, 9] . Therefore, smoking status was the self-reported response to the question 'When was the last time you smoked, or even tried, a cigarette?'.
Secondary outcomes
Secondary cessation outcomes
Secondary cessation outcomes were: imputed missing = smoking 30-day PPA, complete case 7-day PPA and imputed missing = smoking 7-day PPA.
Engagement outcomes
Measures of website engagement were collected for 12 months after randomization. The number of times a participant logged in, length of use of the website from first to last login in days, time spent on each session in minutes, number of web pages visited per login and time spent on each web page in minutes were calculated from data logged automatically by the secured server. Any user activity occurring more than 15 minutes from the previous activity was considered a new login. Participants in the top 25% of number of logins for their assigned website were considered 'high engagers'.
Treatment satisfaction outcomes
Treatment satisfaction outcomes were the extent to which: (1) the assigned website was useful for quitting, (2) the user was satisfied with the assigned website and (3) the user would recommend the assigned website to a friend; example item: 'Would you recommend your assigned website to a friend?'. Response choices for all items ranged from 'not at all' (1) to 'very much' (5), and were dichotomized at a threshold of 'somewhat' (3) or higher.
Statistical analyses
Specified a priori as the primary outcome was the 12-month follow-up 30-day PPA using a complete case analysis in which those who did not provide follow-up data were excluded. As secondary outcomes, 30-and 7-day PPA were also examined among all enrolled participants with missing cases imputed as smokers, and complete case 7-day PPA was also examined. While some research suggests that missing = smoking outcomes may be biased [29, 30] , they are recommended by the Russell Standard [31] to allow for comparison of results with prior web-delivered intervention trials and provide a sensitivity analysis. We used logistic regression models for the cessation outcome as well as secondary binary outcomes related to cessation and treatment satisfaction. Negative binomial models were used to assess differences between treatment arms for zero-inflated count outcomes (e.g. number of logins), while generalized linear models were used for continuous outcomes. We controlled for multiple comparisons in all secondary and subgroup analyses using the Holm procedure [32] . We evaluated the Bayes factor for the primary cessation outcome to provide a summary of the presence and magnitude of the treatment effect [33, 34] . All statistical tests were two-sided, with α = 0.05, and analyses were completed using R version 3.3.0 [35] and R packages BayesFactor [36] and MASS [37] .
Baseline balance and covariate adjustment
Baseline characteristics were balanced between treatment groups, except that the WebQuit arm had slightly more married participants than the Smokefree arm (39 versus 35%, P = 0.040). However, marital status was not associated with cessation outcomes, so was not included as a covariate. We adjusted for the three stratification variables used in randomization to avoid losing power and obtaining incorrect confidence intervals [38] .
RESULTS
Participant characteristics
Participant baseline characteristics are shown in Table 1 . Overall, these characteristics were very similar to those of prior published web-delivered smoking intervention trials [8, 9] .
Participant retention
The data retention rate was 88% (2309 of 2637) and did not differ between arms (WebQuit: 87% (1141 of 1319); Smokefree: 89% (1168 of 1318); odds ratio [(OR) = 0.82 (0.65, 1.04), P = 0.096]. Participants completed the 12-month follow-up survey via web (92% of respondents), telephone (3%), mail (3%) and by postcard short survey of primary and selected secondary outcomes (2%). Sixty-five percent of those who completed the survey did so within 24 hours of receiving the e-mail invitation that noted the $10 bonus incentive.
Primary cessation outcome
The 30-day PPA rates at the 1-year follow-up were 24% for WebQuit.org and 26% for Smokefree.gov ( Table 2 ). The Bayes factor for the primary abstinence outcome was 0.17, indicating 'substantial' evidence for the null hypothesis of no difference between groups [39] .
Secondary outcomes
The missing = smoking 30-day PPA rate at the 12-month follow-up was 21% for WebQuit and 23% for Smokefree. The complete case 7-day PPA rate at the 12-month follow-up was 30% (missing = smoking rate: 26%) for WebQuit, compared to the 32% (missing = smoking rate: 28%) abstinence rate for Smokefree. Further secondary outcomes are available in the Supporting information, Table S1 .
Among high engagers, the 30-day PPA rate at the 12-month follow-up was 30% for each website. In addition, the two arms' 30-day PPA rates did not differ by race/ethnicity, gender, education level, age, employment status, sexual orientation, baseline depression or anxiety, smoking history, baseline friend and partner smoking, baseline acceptance of cravings or other baseline variable in Table 1 (all P > 0.050).
Among those who were highly engaged with their website, WebQuit participants had a higher increase in acceptance of cravings to smoke than Smokefree participants (0.19 versus 0.08 increase; P = 0.034). Each oneunit increase, from baseline to 3-month follow-up, in the acceptance of cravings score was associated strongly with 30-day PPA at 12-month follow-up among all participants (OR = 4.11; 95% CI = 3.40-4.97). 
Utilization and satisfaction
As shown in Table 3 , compared to Smokefree, WebQuit participants had a higher (1) average number of logins, (2) average time spent on each login session and (3) average number of web pages visited per login. The average length of website usage was the same in both programs at 57 days. Participants in both arms reported high satisfaction with their assigned website, although satisfaction was somewhat higher in the WebQuit arm. For example, 95% of WebQuit participants would recommend the website to a friend, compared to 90% for Smokefree.
DISCUSSION
To overcome the limitations of prior trials of web-delivered cessation interventions, we conducted a trial comparing the quit rates of a website using a new approach called Acceptance and Commitment Therapy (ACT; WebQuit.org) with the National Cancer Institute's (NCI) Smokefree.gov website for cessation. Twelve-month, 30-day point prevalence quit rates were high in both arms (26% for Smokefree; 24% for WebQuit). These quit rates were almost three times higher than the 9% weighted average quit rates obtained in prior web-based randomized trials Table 2 Smoking cessation outcomes at 12-month follow-up. complete case analysis (i.e. exclusion of participants lost to follow-up) was specified a priori as the primary outcome; c the missing = smoking outcomes are provided as recommended by the Russell Standard. PPA = point prevalence abstinence; OR = odds ratio. Table 3 Treatment engagement and satisfaction. All items were assessed at 12-month follow-up, with the exception of the last two, satisfaction and recommendation, which were assessed at 3-month follow-up. with at least 12-month follow-up [8] . Moreover, the quit rates were more than one-and-a-half times higher than the 14% weighted average quit rates obtained in prior randomized trials of telephone interventions with at least 12-month follow-up (range = 8-20% [11] .
Quit rates
Comparing the pilot trial [14] with the current full-scale trial, one pattern of results is striking: the WebQuit abstinence rate stayed approximately the same (23% 3-month 30-day quit rate in the pilot compared to 24% 12-month 30-day quit rate in the current trial), while the Smokefree abstinence rate more than doubled (10% 3-month 30-day quit rate in the pilot compared to 26% in the current trial). This increase was due potentially to the study design of the pilot [14] versus the current study: the pilot trial had a smaller sample size (222 versus 2637) and lower retention rate (54% versus 88%), thus making the point estimate of the pilot less reliable [14] . Other reasons might be the synergistic effect of Smokefree content and design revisions that NCI made before the start of the current trial, including: (1) a front-page feature called 'I'm craving cigarettes' that provided advice on how to cope with cravings; (2) a front-page feature called 'I feel depressed' that provided advice on how to cope with depressive symptoms; (3) an interactive feature for selecting pharmacotherapy for smoking cessation, including comparisons of efficacy, cost and side effects; (4) a graphical interactive feature for viewing the health effects of smoking and quitting; and (5) improved site navigability and page layout.
Engagement and satisfaction
Participants were more engaged with WebQuit than Smokefree and were slightly more satisfied than Smokefree participants. High engagers had higher quit rates and, in general, engagement in web-delivered programs is a wellknown predictor of cessation [40] . There are a variety of potential reasons why WebQuit users were more engaged. First, participants may have found the ACT content novel and thought-provoking. To support this possibility, in qualitative data from the outcome survey, participants made comments such as: 'I especially liked the advice to ride with the urges to smoke rather than to try to ignore them or replace them with diversion'. Additionally, WebQuit was a structured program with its main content funneling users in a logical order, and evidence suggests that funneling improves engagement [41, 42] .
Implications for ACT research
The current study provides the largest randomized trial of ACT conduced to date. As of May 2017, there were 175 published peer-reviewed randomized controlled trials of ACT, focusing upon a variety of outcomes including weight loss and pain management [43] . Of these, 22% had a sample size of ≥ 100 (n = 39 [43] ) and 3% had ≥ 300 participants (n = 6 [43] ), with the largest having 586 participants [44] . Of the trials with ≥ 300 participants, the average follow-up length was 8 months and the average retention rate was 60%. Similar to prior ACT trials, the current trial shows that ACT increases acceptance of internal experiences (e.g. cravings) among those who engage with the content, and this acceptance in turn has a strong positive impact upon clinical outcomes. The theoretical premise of the ACT model is therefore supported.
As to why increased acceptance in the ACT arm did not translate into quit rates higher than the control, we speculate that the control arm had unique theoretical processes that positively and equally impacted its quit rate relative to the ACT arm. Overall, the current study provides a methodologically robust contribution to the ACT scientific literature, and suggests that the ACT model is a reasonable alternative to mainstream approaches to smoking cessation.
Strengths
This study has a number of strengths, including a large sample and long-term follow-up. Most notably, the trial's 88% 12-month outcome retention rate contributes to confidence in the study findings. Several design factors are believed to contribute to the high retention rate: (1) $25 cash for completing the outcome surveys, (2) $10 bonus cash for completing the web-based survey within 24 hours and (3) having four methods (web, telephone, mail and postcard) to complete the survey that were offered in sequence (instead of in parallel, which is known to reduce overall response rate [45] ). This 88% retention was more than 2.5 times higher than the average rate (34%) obtained in prior trials with at least 12-month follow-up [8, 9] .
Limitations
This study has several limitations. First, cessation outcome data were self-reported for reasons stated in the Methods. Remote biochemical validation of smoking cessation would have introduced biases including low response rates, challenges with confirming the identity of the person providing the sample, inability to confirm abstinence beyond 24 hours and false-positive errors due to second-hand smoke. Secondly, without a third minimal treatment arm (e.g. print-based self-help material), it is possible that the observed quit rates would have been achieved with little intervention if participants were highly motivated to quit. However, we think that is highly unlikely for several reasons: (1) the inclusion criteria, recruitment methods and baseline characteristics of the sample were very similar to prior trials with at least 12-month follow-up [8] ; (2) smoking cessation self-help materials have low (6%) quit rates [46] ; and (3) users' baseline motivation to quit was very similar to other trials of web-delivered smoking cessation [8, 9] . For these reasons, we considered and then rejected the idea of a minimal intervention third arm when planning the trial. Thirdly, only 23.8% (2637 of 11 070) of those screened were randomized into the trial. This level of selection bias is highly consistent with prior published webdelivered smoking intervention trials [8, 9] and with prior telephone-delivered cessation intervention trials [11] . Indeed, in one of the largest randomized trials of telephonedelivered smoking cessation [47] , only 18.5% of those screened were randomized (4614 of 24 089). Note also that the allocation sequence was concealed from investigators, and the inclusion criteria, recruitment methods and baseline characteristics were very similar to prior web-delivered cessation trials [9] . Loss to follow-up is another potential source of bias; however, because retention rates were high and did not vary between arms, and because the missing = smoking analysis led to a similar conclusion as complete case analysis, this potential bias was minimized.
CONCLUSION
This trial identified two websites that obtained 12-month quit rates higher than any prior published website-or telephone counselor-delivered intervention trial for smoking cessation. To illustrate the potential public health impact, consider that impact is a product of reach and efficacy [48] . The projection derived from the current research trial's conditions is that for every 1 million smokers reached with either website, at least 240 000 would quit smoking. Both websites are helpful options for people seeking on-line help quitting smoking.
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